肺癌血管靶向有效治疗新进展.pptVIP

1.Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The endpoints were overall survival (OS), progression-free survival (PFS) and side effects. 2.We analyzed the use of Bev in the doses of 7.5 mg/kg and 15 mg/kg. 3.The final analysis included 4 trials, comprising 2200 patients. The combination of CT plus Bev increased the response rate and progression-free survival of patients with NSCLC. With respect to overall survival the benefits of Bev remains uncertain. * * In conclusion, addition of bevacizumab to first-line CP results in similar PFS benefits in Japanese